Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Deals Of The Week: Onyx Proteolix, Novartis/Heptares, Wyeth/Progenics ...

  • News

Executive Summary

Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.

You may also be interested in...



Deals Of The Week: Shire/Heptares, NicOx/Altacor, UCB/Oxford University

This past week saw two GPCR-focused deals – Shire’s optioning of a preclinical adenosine A2a antagonist and Anaphore’s acquisition of a platform company specializing in biologics targeting GPCRs.

Shire To Strengthen CNS Focus With Option On Heptares' Novel Parkinson's Therapy

Shire Pharmaceuticals takes an option on Heptares' efforts to develop novel adenosine antagonists for Parkinson's disease.

Shire To Strengthen CNS Focus With Option On Heptares' Novel Parkinson's Therapy

Shire Pharmaceuticals takes an option on Heptares' efforts to develop novel adenosine antagonists for Parkinson's disease.

Table

View full table

Related Content

Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

Keeping Track: Pharming’s Joenja, Cidara’s Rezzayo And Incyte’s Zynyz Headline US FDA Approval Bonanza

House QALY Bill Overreach Threatens Medicare Price Negotiation Program, Democrats Warn

Recent And Upcoming FDA Advisory Committee Meetings

iPLEDGE REMS: FDA Panel To Consider Changing Pregnancy Testing, Counseling Requirements

See All
UsernamePublicRestriction

Register

PS051582

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By